Insider Trading July 9, 2026 04:42 PM

Privia Health CFO Mountcastle Executes Stock Sale Under Pre-Arranged Plan

Executive Vice President and CFO David Mountcastle divests 600 shares valued at $16,542, while the company navigates mixed Q1 earnings and governance updates.

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
PRVA

David Mountcastle, Executive Vice President and Chief Financial Officer of Privia Health Group, Inc. (NASDAQ:PRVA), executed a sale of 600 shares of the company's common stock on July 7, 2026. The transaction, valued at $16,542, was facilitated through a Rule 10b5-1 trading plan, which establishes a predetermined schedule for insider transactions. This sale reduces Mountcastle's direct holdings to 186,128 shares, with an additional 8,695 shares held indirectly by his spouse. The transaction occurs as PRVA trades near its 52-week high, reflecting a 28% one-year return, though recent financial data presents a mixed outlook for the healthcare entity.

Privia Health CFO Mountcastle Executes Stock Sale Under Pre-Arranged Plan
PRVA
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • CFO Mountcastle sold 600 shares via a Rule 10b5-1 plan, reducing direct holdings to 186,128 shares.
  • PRVA stock trades near 52-week highs with a 28% one-year return, though analysts see slight undervaluation.
  • Q1 2026 earnings showed a revenue beat of 7.93% but an EPS miss of 73.19%, alongside governance updates.

David Mountcastle, serving as Executive Vice President and Chief Financial Officer for Privia Health Group, Inc. (NASDAQ:PRVA), completed a divestment of 600 shares of the company's common stock on July 7, 2026. The total value realized from this transaction was recorded at $16,542. The shares were liquidated at prices fluctuating between $27.55 and $27.58 per share, resulting in a weighted average sale price of $27.57. This execution was conducted under the parameters of a Rule 10b5-1 trading plan, a mechanism that permits insiders to establish a fixed schedule for buying or selling company equity in advance.

Following the completion of this sale, Mountcastle's direct ownership stake in Privia Health Group stands at 186,128 shares. Furthermore, an additional 8,695 shares are maintained indirectly through his spouse. The timing of this insider transaction coincides with PRVA trading at $27.77, a level closely aligned with its 52-week high of $27.70. Over the preceding year, the stock has generated returns of 28%. According to analysis from InvestingPro, the current valuation suggests the stock may be slightly undervalued. Market analysts maintain a bullish stance on the healthcare company, with price targets established between $24 and $40.

Recent corporate developments provide additional context for investors. Privia Health Group reported its first-quarter 2026 earnings, revealing a mixed financial performance. The company missed earnings per share expectations, posting an EPS of $0.02 against a forecast of $0.0746, marking a 73.19% shortfall. Conversely, revenue surpassed projections, achieving $603.85 million compared to the expected $559.49 million, representing a 7.93% positive surprise. Additionally, shareholders approved all proposals at the 2026 Annual Meeting of Stockholders. This approval included the election of three Class I directors: Nancy Cocozza, David King, and Francis Soistman, who will serve until the 2029 Annual Meeting. These events underscore significant financial and governance dynamics for stakeholders to evaluate.

Risks

  • The significant 73.19% miss on earnings per share highlights potential volatility in profitability metrics for the healthcare sector.
  • Mixed financial results, with revenue growth offset by earnings shortfalls, may impact investor sentiment and market valuations.

More from Insider Trading

AppFolio (APPF) 10% Owner Duca Sells $1.93M in Stock Jul 9, 2026 Abeona Therapeutics Executive Sells Stock to Cover Tax Obligations as Q1 Earnings Beat Jul 9, 2026 Abeona Therapeutics Executive Disposes of Shares to Cover Tax Liabilities Jul 9, 2026 Wrap Technologies Director Shulman Acquires Shares Amid Product Expansions Jul 9, 2026 WRAP Technologies CEO Scot Cohen Acquires Shares Amid Product Launches and Regulatory Clarity Jul 9, 2026